Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
5.32
+0.55 (11.53%)
At close: Aug 4, 2025, 4:00 PM
5.34
+0.02 (0.38%)
After-hours: Aug 4, 2025, 6:58 PM EDT

Company Description

Lantern Pharma Inc. focuses on the discovery and development of oncology drug.

Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma.

The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers.

In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.

The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases.

The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Inc.
Lantern Pharma logo
CountryUnited States
Founded2013
IPO DateJun 11, 2020
IndustryBiotechnology
SectorHealthcare
Employees24
CEOPanna Sharma

Contact Details

Address:
1920 McKinney Avenue, 7th Floor
Dallas, Texas 75201
United States
Phone972 277 1136
Websitelanternpharma.com

Stock Details

Ticker SymbolLTRN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001763950
CUSIP Number51654W101
ISIN NumberUS51654W1018
Employer ID46-3973463
SIC Code2834

Key Executives

NamePosition
Panna SharmaPresident, Chief Executive Officer and Director
David R. MargraveChief Financial Officer and Secretary
Dr. Kishor Gopaldas Bhatia Ph.D.Chief Scientific Officer and Scientific Consultant
Dr. Peter L. Nara D.V.M., M.S., Ph.D.Co-Founder and Advisor
Ernest Kitt B.S., M.SHead of Clinical Operations
Dr. Marc C. Chamberlain M.D.Chief Medical Officer of Starlight Therapeutics

Latest SEC Filings

DateTypeTitle
Jul 29, 20258-KCurrent Report
Jul 28, 2025PRE 14AOther preliminary proxy statements
Jul 3, 20258-KCurrent Report
Jul 3, 2025424B5Filing
Jun 13, 2025SCHEDULE 13D/AFiling
May 27, 2025144Filing
May 27, 2025144Filing
May 27, 2025144Filing
May 27, 2025144Filing
May 27, 2025144Filing